Jayne Galinsky

Research Fellow | GCU | Views my own.

[Jayne Galinsky @Jaynegalinsky]

v happy to have this preference elicitation study in ATTR-CM published from my former role, which was conducted with and written together with patient orgs - https://t.co/ekmPdQjJAI
@hATTRCanada @Cardiomyopathy @RTIHS

[Jayne Galinsky @Jaynegalinsky]

@KEC83 @Cancer_Nursing Congratulations!

[Christina Boswell @BoswellPol]

We are recruiting 30 - yes, that's right, 30! - Chancellor's Fellows to prestigious, tenure-track, research-intensive early/mid-career roles at the University of Edinburgh. Please spread the word!

[Jayne Galinsky @Jaynegalinsky]

@Bookbug_SBT @TalesOfOneCity @GlasgowLib @MidLibraries @InverclydeLibs @LibrariesNL @eastlothianlibs @salibraries @LeithLibrary! With the best staff and bookbugs

[Jayne Galinsky @Jaynegalinsky]

@auner_lab_ICL @ImperialImmuno congratulations Holger!

[Jayne Galinsky @Jaynegalinsky]

@avallejo_ @MyelomaEurope Yay!!

[Jayne Galinsky @Jaynegalinsky]

So excited to be talking at this session on patient preferences and clinical trials at my first in person conference for years, in beautiful Chicago, and at DIA! #DIA2022

[ICON Plc @ICONplc]

Join @ICONplc's Jayne Galinsky and industry experts at #DIA2022 as they discuss assessing and integrating patient preferences into treatment and #clinicaltrial design: https://t.co/ABmw7OoLkq

[Jayne Galinsky @Jaynegalinsky]

@MyelomaEurope @HansScheurer @KateEMor_ @avallejo_ @Celenapalma @LindaChris0408 @vinceclaus @EHA_Hematology You all look amazing! I'm so happy for you to meet each other in person finally!

[Jayne Galinsky @Jaynegalinsky]

@LizForbat Congratulations!!! 🥰

[Jayne Galinsky @Jaynegalinsky]

@MyelomaEurope Such exciting news! ⭐️

[Jayne Galinsky @Jaynegalinsky]

@ShelaghMckinlay @amy_B3ar @DrSStern @c_messiou @Suzanne_Renwick Congratulations all. Impressive work

[Paul Kluetz @pkluetz]

I have spent a lot of time looking at how patients can generate data on drug side effects in cancer trials. This session will really delve into tolerability, what it means to patients, and how we might better measure it. Tune in if you can. @FDAOncology @vishalbmd #PFDD

[Jayne Galinsky @Jaynegalinsky]

Superstar friend ⭐️

[Chris Dixon @_C_Dixon]

This was a good moment ☺️🤳

[Mel Calvert @drmelcalvert]

If you are using #patientreportedoutcomes in #trials then please check out our latest paper from the #proteus consortium led by Claire Snyder - 6 🛠 to help support your work @andrewbottom0 @nlcrossnohere @ReeveBryce @SydneyQOLO @CPROR_UoB @sisaqol #pros

[Jayne Galinsky @Jaynegalinsky]

@DanielCairns1 @MyelomaUK @ShelaghMckinlay @amy_B3ar Congratulations @MyelomaUK policy team!!

[NHS Research Scotland @NHSResearchScot]

.@CSO_Scotland has launched a new Fellowship scheme to provide 3 years of funding to researchers that have just completed a PhD and are looking to take the next step in developing a research career.

Read more and apply 👉 https://t.co/40eskwRh6C

[Simon Fifer @simonfifer]

Do patient preferences influence HTA Decisions? Good question. Check out our latest webinar #patientvoice #hta #preferences https://t.co/n8kXqI2J2F

[Jayne Galinsky @Jaynegalinsky]

@DrAshleyRogers @AbertayUni @StirUni @StirlingUniCrim @TheSCCJR Congratulations!!

[Holger W. Auner @auner_lab_CH]

FULLY FUNDED 3 YEAR PhD studentship in Cancer Biology & Biomechanics in my lab @ImperialImmuno and with @GentlemanLab across town.
Join us to study the biology of cancers including #myeloma at a world top ten university. Please RT, details here: https://t.co/zS0lAQnpka

[Gareth Morgan @DrGarethMorgan1]

Interesting discussion in our clinical meeting. Is there an age cutoff for ASCT? ⁦@theMMRF⁩ ⁦@nyulangone⁩ #mmsm
Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old. https://t.co/yGOPfeYXIO